Elite Pharmaceuticals, Inc. Proceeds from Notes Payable
Elite Pharmaceuticals, Inc. (ELTP) reported Proceeds from Notes Payable of $14.44 million for the 12-month period ending 2023-03-31, per its 10-K filed 2024-07-01.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromNotesPayable · last filed 2024-07-01
- Elite Pharmaceuticals, Inc. proceeds from notes payable for the quarter ending 2023-03-31 was -$111.02K.
- Elite Pharmaceuticals, Inc. proceeds from notes payable for the quarter ending 2022-12-31 was $1.00.
- Elite Pharmaceuticals, Inc. proceeds from notes payable for the quarter ending 2022-09-30 was $2.55M.
- Elite Pharmaceuticals, Inc. proceeds from notes payable for the quarter ending 2022-06-30 was $12.00M.
- Elite Pharmaceuticals, Inc. proceeds from notes payable for fiscal 2023 was $14.44M.
| Period end | Proceeds from Notes Payable 3 month | Proceeds from Notes Payable 6 month | Proceeds from Notes Payable 9 month | Proceeds from Notes Payable 12 month |
|---|---|---|---|---|
| 2023-03-31 | -$111.02K derived: 10-K 12 month − 10-Q 9 month · filed 2024-07-01 | -$111.02K derived: sum of 2 quarters · filed 2024-07-01 | $2.44M derived: sum of 3 quarters · filed 2024-07-01 | $14.44M 10-K · filed 2024-07-01 |
| 2022-12-31 | $1.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-02-14 | $2.55M derived: sum of 2 quarters · filed 2024-02-14 | $14.55M 10-Q · filed 2024-02-14 | |
| 2022-09-30 | $2.55M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-11-14 | $14.55M 10-Q · filed 2023-11-14 | ||
| 2022-06-30 | $12.00M 10-Q · filed 2023-08-14 |